Dianthus Therapeutics, Inc.
DNTH scores 15.0 on the Conservative profile, blending a fundamental score (80% weight, emphasizing quality and stability (84% of fundamental weight)) with a machine-learning signal (20% weight) trained on 82 features across 30 years of data.
Net penalties of -28.0 points significantly impact the ranking. Without these adjustments, DNTH would rank considerably higher.
These features are direct inputs to the machine learning model. The model was trained on these signals alongside 100 features (including 12 momentum/technical indicators) to produce the ML percentile score.
| Stock | Score | P/E | Rev Growth | Margin | Mkt Cap |
|---|---|---|---|---|---|
| DNTH | 15.0 | N/A | 120.6% | -4104.8% | $1.8B |
| INCY | 89.9 | 15.8 | 21.2% | 25.0% | $19.6B |
| GMAB | 86.1 | 13.1 | 22.8% | 36.4% | $17.9B |
| CPRX | 83.7 | 13.7 | 23.5% | 37.6% | $3.0B |
| ASND | 78.3 | 16.6 | 98.0% | -31.7% | $13.8B |
| EXEL | 78.3 | 15.1 | 7.0% | 33.7% | $11.9B |
| VRTX | 78.2 | 32.1 | 8.9% | 32.9% | $121.8B |
| NBIX | 75.1 | 26.5 | 21.4% | 16.7% | $13.1B |
| RPRX | 75.0 | 25.1 | 5.1% | 32.4% | $19.3B |
| HOLX | 74.8 | 31.1 | 1.7% | 13.8% | $16.8B |
| AMGN | 74.2 | 26.0 | 10.0% | 21.0% | $204.8B |
| ARGX | 73.7 | 35.1 | 78.6% | 38.0% | $47.4B |
| REGN | 73.0 | 19.4 | 1.0% | 31.4% | $80.2B |
| ALKS | 72.9 | 16.5 | -6.4% | 23.9% | $5.0B |
| ISRG | 72.7 | 61.7 | 20.5% | 28.4% | $180.9B |
| KRYS | 71.5 | 41.4 | 473.0% | 30.7% | $7.9B |
| Sector Average | 36.6 | 41.9 | 161.5% | -3292.7% | โ |
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
Stock is in an uptrend above the 200-day moving average. This is the stage where institutional accumulation typically occurs. The 50-day SMA provides support.
| Metric | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| Revenue | $396,000 | $193,000 | $1M | $1M |
| Gross Profit | $396,000 | $193,000 | $1M | $1M |
| Operating Income | $-40M | $-35M | $-33M | $-32M |
| Net Income | $-37M | $-32M | $-30M | $-28M |
| EPS (Diluted) | $-0.97 | $-0.88 | $-0.82 | $-0.81 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -10173.7% | -18096.9% | -2852.7% | -2406.9% |
| Net Margin | -9284.1% | -16388.1% | -2537.5% | -2144.8% |
| Year | Low | High | Range | Status |
|---|---|---|---|---|
| 2021 | $70.40 | $227.20 | 105.4% | Wide |
| 2022 | $5.14 | $87.84 | 177.9% | Wide |
| 2023 | $5.89 | $14.46 | 84.2% | Wide |
| 2024 | $10.22 | $33.77 | 107.1% | Wide |
| 2025 | $13.37 | $45.46 | 109.1% | Wide |
Scores are generated by a multi-stage ML pipeline combining fundamental analysis, ensemble predictions, and structural risk signals. All data is for research purposes only and does not constitute financial advice. Past performance does not guarantee future results.